Cannabinoid Encyclopedia

Health and effects

Cannabinoids and Inflammation-related outcomes

What studies can tell us about cannabinoids and Inflammation-related outcomes, including human research, early evidence, and important limits.

Updated July 2026 58 research sources Human and early research

The short answer

What does the research say about Inflammation-related outcomes?

Researchers have studied cannabinoids in connection with Inflammation-related outcomes. The current literature covers CBG, CBC, THCV, and CBDA. This page brings together 15 human-study sources, 11 research reviews, and 26 lab, animal, or mechanism sources. The source set includes human research as well as earlier-stage studies. There is no single answer that applies to every cannabinoid, dose, product, or person. 1

Choose your next step

Want the quick path or the full picture?

Use this guide the way you need to. Start with the practical question, then open the study detail only when it helps answer something about Inflammation-related outcomes.

What researchers studiedSee the main areas and the evidence behind each one. Safety and limitsKeep product, dose, medications, and context in view. Open the sourcesGo directly to the studies and references used here.

Key takeaways

What to know first

  1. 1

    Research on Inflammation-related outcomes covers CBG, CBC, and THCV; those areas should not be combined into one claim. 1

  2. 2

    The source set includes human research as well as earlier-stage studies. 2

  3. 3

    Dose, formulation, route, study population, and outcome can change how closely a study applies to a real-world question. 3

Research areas

What researchers studied about Inflammation-related outcomes

These are the main questions represented in the current literature. Each link opens a source used to build the overview.

Preclinical and mechanism-focused

CBG

Researchers have studied CBG in connection with Inflammation-related outcomes. The exact compound, dose, formulation, sleep or health measure, and study design determine what the source can show. 2

Human and early-stage research

CBC

Researchers have studied CBC in connection with Inflammation-related outcomes. The exact compound, dose, formulation, sleep or health measure, and study design determine what the source can show. 3

Mostly mechanism-focused

THCV

Researchers have studied THCV in connection with Inflammation-related outcomes. The exact compound, dose, formulation, sleep or health measure, and study design determine what the source can show. 4

Preclinical and mechanism-focused

CBDA

Researchers have studied CBDA in connection with Inflammation-related outcomes. The exact compound, dose, formulation, sleep or health measure, and study design determine what the source can show. 5

How strong is the research?

Not every study answers the same question

This page separates research in people, research reviews, and earlier-stage biology before interpreting the larger question.

15 sources

Human studies

Research involving people is closest to everyday health questions. The product, dose, population, and outcome still determine what each study can show.

11 sources

Reviews and evidence summaries

Reviews can compare several studies at once. Their conclusion is only as strong and as relevant as the studies they include.

26 sources

Lab, animal, and mechanism research

Early-stage research can explain biological interest. It cannot, by itself, show that the same effect happens in people.

Another 6 of 58 research sources could not be placed cleanly into those three groups from the recorded study details.

What these studies actually looked at

The research on Inflammation-related outcomes is not one kind of study. This source set includes 31 animal studies, 9 narrative or expert reviews, 7 cell or laboratory studies, and 2 systematic reviews or meta-analyses. 3

The recorded populations or models include animal models (24 sources), people or patients (18 sources), and cells or tissue models (6 sources). A result from one group or model should not be assumed to apply to another. 4

The most common recorded outcome focus is inflammation-related or immune outcomes (28 sources), nausea-related or inflammation-related outcomes (25 sources), and inflammation-related or pain-related outcomes (9 sources). Closely related outcome names can still describe different measurements. 5

The Inflammation-related outcomes source set also contains findings or reviews that remain too limited, indirect, or mixed for a broad answer. That uncertainty is part of the result, not an empty space to fill with assumptions. 6

Examples from the literature

What did the studies actually look at?

Each example names the research question and the study details recorded for that source.

narrative or expert review

(‒)-Cannabidiolic Acid, a Still Overlooked Bioactive Compound: An Introductory Review and Preliminary Research.

On this page, this source examines CBDA and nausea-related or inflammation-related outcomes. 1

Study type
narrative or expert review
Outcome focus
nausea-related or inflammation-related outcomes
Evidence stage
evidence still limited

narrative or expert review

Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential.

On this page, this source examines CBG and inflammation-related outcomes. 2

Study type
narrative or expert review
Population or model
people or patients
Outcome focus
inflammation-related or immune outcomes
Evidence stage
evidence still limited

narrative or expert review

Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.

On this page, this source examines CBC and inflammation-related outcomes and CBG and inflammation-related outcomes. 3

Study type
narrative or expert review
Population or model
people or patients
Outcome focus
inflammation-related or pain-related outcomes and inflammation-related or immune outcomes
Evidence stage
evidence still limited

cell or laboratory study

Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages.

On this page, this source examines CBC and inflammation-related outcomes and THCV and inflammation-related outcomes. 4

Study type
cell or laboratory study
Population or model
people or patients
Outcome focus
inflammation-related or pain-related outcomes and inflammation-related or immune outcomes
Evidence stage
mechanism-focused research

narrative or expert review

Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer.

On this page, this source examines CBDA and nausea-related or inflammation-related outcomes. 5

Study type
narrative or expert review
Population or model
cells or tissue models
Outcome focus
nausea-related or inflammation-related outcomes
Evidence stage
evidence still limited

Safety and limits

What should readers keep in mind?

Research on Inflammation-related outcomes should be read beside safety. A compound can be non-intoxicating or naturally occurring and still have pharmacologic effects, side effects, interactions, or product-quality concerns. 2

Research doses are descriptions of what a study tested. They are not personal dosing instructions. Questions involving medications, pregnancy, children, driving, liver health, heart health, or serious symptoms deserve professional medical guidance.

Drug interactions Pregnancy and children Driving and impairment All safety topics

Common questions

Questions people ask

Can cannabinoids help with Inflammation-related outcomes?

Research exists, but there is not one answer for every cannabinoid or product. The source set includes human research as well as earlier-stage studies. 7

Why can studies reach different answers?

Studies may test different cannabinoids, doses, formulations, routes, people, and outcomes. Those differences can change the result. 8

What should I check in a study?

Check whether it studied people, what product and dose it used, what it measured, how long it lasted, and whether safety was reported. 9

Sources

Read the research

The numbered sources below support the main overview. Links open the PubMed record or DOI in a new tab.

  1. 1
    (‒)-Cannabidiolic Acid, a Still Overlooked Bioactive Compound: An Introductory Review and Preliminary Research. narrative or expert review; evidence still limited PubMed 32517131 DOI 10.3390/molecules25112638
  2. 2
    Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential. narrative or expert review; evidence still limited PubMed 39598860 DOI 10.3390/molecules29225471
  3. 3
    Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. narrative or expert review; evidence still limited PubMed 21749363 DOI 10.1111/j.1476-5381.2011.01238.x
  4. 4
    Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages. cell or laboratory study; mechanism-focused research PubMed 37764262 DOI 10.3390/molecules28186487
  5. 5
    Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer. narrative or expert review; evidence still limited PubMed 30627539 DOI 10.1155/2018/1691428
  6. 6
    The Effects of Cannabinoids on Pro- and Anti-Inflammatory Cytokines: A Systematic Review of In Vivo Studies. systematic review or meta-analysis; evidence still limited PubMed 33998900 DOI 10.1089/can.2020.0105
  7. 7
    The Use of Cannabinoids in Colitis: A Systematic Review and Meta-Analysis. systematic review or meta-analysis; evidence still limited PubMed 29562280 DOI 10.1093/ibd/izy014
  8. 8
    A comparison of cannabidiolic acid with other treatments for anticipatory nausea using a rat model of contextually elicited conditioned gaping. clinical study in people; mechanism-focused research PubMed 24595502 DOI 10.1007/s00213-014-3498-1
  9. 9
    Therapeutic potential of cannabidiol-rich Cannabis sativa to mitigate the severity of inflammation and pain: A pre-clinical study. human research PubMed 41213439 DOI 10.1016/j.jep.2025.120856
  10. 10
    Cannabigerol and cannabichromene in Cannabis sativa L. narrative or expert review; evidence still limited PubMed 36654096 DOI 10.2478/acph-2021-0021
  11. 11
    Effects of Cannabidiol on Locomotor Activity. narrative or expert review; evidence still limited PubMed 35629320 DOI 10.3390/life12050652
  12. 12
    Medical Cannabis Activity Against Inflammation: Active Compounds and Modes of Action. narrative or expert review; evidence still limited PubMed 35614947 DOI 10.3389/fphar.2022.908198
See all 58 research sources

This complete source list is the deeper research layer for the page. Study type and evidence context are shown when they are available in the current record.

  1. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. narrative or expert review; evidence still limited / 2 linked research notes PubMed 21749363
  2. Anti-inflammatory and analgesic potential of minor cannabinoids in vivo. animal study; mechanism-focused research / 1 linked research note PubMed 41680865
  3. The Mechanism of Cannabichromene and Cannabidiol Alone Versus in Combination in the Alleviation of Arthritis-Related Inflammation. animal study; preclinical research / 1 linked research note PubMed 37332213
  4. Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer. narrative or expert review; evidence still limited / 1 linked research note PubMed 30627539
  5. Therapeutic potential of acidic cannabinoids: an update. narrative or expert review; evidence still limited / 2 linked research notes PubMed 41545891
  6. Therapeutic potential of cannabidiol-rich Cannabis sativa to mitigate the severity of inflammation and pain: A pre-clinical study. human research / 1 linked research note PubMed 41213439
  7. Entourage effects of nonpsychotropic cannabinoids on visceral sensitivity in experimental colitis. animal study; preclinical research / 2 linked research notes PubMed 39921943
  8. Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages. cell or laboratory study; mechanism-focused research / 2 linked research notes PubMed 37764262
  9. Minor Cannabinoids CBD, CBG, CBN and CBC differentially modulate sensory neuron activation. animal study; mechanism-focused research / 1 linked research note PubMed 41256665
  10. Minor cannabinoids CBD, CBG, CBN, and CBC differentially modulate sensory neuron activation. animal study; mechanism-focused research / 1 linked research note PubMed 42139799
  11. Therapeutic Potential of Cannabidiol, Cannabidiolic Acid, and Cannabidiolic Acid Methyl Ester as Treatments for Nausea and Vomiting. narrative or expert review; evidence still limited / 1 linked research note PubMed 34115951
  12. Cannabidiolic acid methyl ester, a stable synthetic analogue of cannabidiolic acid, can produce 5-HT1A receptor-mediated suppression of nausea and anxiety in rats. animal study; mechanism-focused research / 1 linked research note PubMed 29057454
  13. Evaluation of Sex Differences in the Potential of Δ9-Tetrahydrocannabinol, Cannabidiol, Cannabidiolic Acid, and Oleoyl Alanine to Reduce Nausea-Induced Conditioned Gaping Reactions in Sprague-Dawley Rats. animal study; preclinical research / 1 linked research note PubMed 35984924
  14. Evaluation of repeated or acute treatment with cannabidiol (CBD), cannabidiolic acid (CBDA) or CBDA methyl ester (HU-580) on nausea and/or vomiting in rats and shrews. animal study; mechanism-focused research / 1 linked research note PubMed 32488349
  15. Effect of combined doses of Δ9-tetrahydrocannabinol and cannabidiol or tetrahydrocannabinolic acid and cannabidiolic acid on acute nausea in male Sprague-Dawley rats. animal study; mechanism-focused research / 1 linked research note PubMed 31897571
  16. Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation. animal study; mechanism-focused research / 1 linked research note PubMed 23121618
  17. Neuromotor tolerability and behavioural characterisation of cannabidiolic acid, a phytocannabinoid with therapeutic potential for anticipatory nausea. animal study; preclinical research / 1 linked research note PubMed 26439367
  18. A comparison of cannabidiolic acid with other treatments for anticipatory nausea using a rat model of contextually elicited conditioned gaping. clinical study in people; mechanism-focused research / 1 linked research note PubMed 24595502
  19. Effect of combined doses of Δ(9)-tetrahydrocannabinol (THC) and cannabidiolic acid (CBDA) on acute and anticipatory nausea using rat (Sprague- Dawley) models of conditioned gaping. animal study; preclinical research / 1 linked research note PubMed 26381155
  20. Suppression of lithium chloride-induced conditioned gaping (a model of nausea-induced behaviour) in rats (using the taste reactivity test) with metoclopramide is enhanced by cannabidiolic acid. animal study; preclinical research / 1 linked research note PubMed 24012649
  21. Short term feeding of industrial hemp with a high cannabidiolic acid (CBDA) content increases lying behavior and reduces biomarkers of stress and inflammation in Holstein steers. evidence still limited / 1 linked research note PubMed 35256692
  22. Antiviral activities of hemp cannabinoids. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 37083031
  23. Effect of cannabidiolic acid and ∆9-tetrahydrocannabinol on carrageenan-induced hyperalgesia and edema in a rodent model of inflammatory pain. animal study; mechanism-focused research / 1 linked research note PubMed 30225659
  24. Medical Cannabis Use and Inflammatory Cytokines and Chemokines Among Adult Chronic Pain Patients. evidence still limited / 1 linked research note PubMed 36342776
  25. Raman-Based Differentiation of Hemp, Cannabidiol-Rich Hemp, and Cannabis. evidence still limited / 1 linked research note PubMed 32401504
  26. Serum cannabidiol, tetrahydrocannabinol (THC), and their native acid derivatives after transdermal application of a low-THC Cannabis sativa extract in beagles. evidence still limited / 1 linked research note PubMed 32735381
  27. Phytochemical Analysis of the Methanolic Extract and Essential Oil from Leaves of Industrial Hemp Futura 75 Cultivar: Isolation of a New Cannabinoid Derivative and Biological Profile Using Computational Approaches. evidence still limited / 1 linked research note PubMed 35807623
  28. The effect of phytocannabinoids on airway hyper-responsiveness, airway inflammation, and cough. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 25655949
  29. (‒)-Cannabidiolic Acid, a Still Overlooked Bioactive Compound: An Introductory Review and Preliminary Research. narrative or expert review; evidence still limited / 1 linked research note PubMed 32517131
  30. Effects of Cannabidiol on Locomotor Activity. narrative or expert review; evidence still limited / 1 linked research note PubMed 35629320
  31. Behavioural and molecular effects of cannabidiolic acid in mice. animal study; mechanism-focused research / 1 linked research note PubMed 32798553
  32. Synergy between cannabidiol, cannabidiolic acid, and Δ⁹-tetrahydrocannabinol in the regulation of emesis in the Suncus murinus (house musk shrew). evidence still limited / 1 linked research note PubMed 26030435
  33. Alginate-based microencapsulation as a strategy to improve the therapeutic potential of cannabidiolic acid. evidence still limited / 1 linked research note PubMed 39667593
  34. Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential. narrative or expert review; evidence still limited / 1 linked research note PubMed 39598860
  35. Orally administered Cannabigerol (CBG) in rats: Cannabimimetic actions, anxiety-like behavior, and inflammation-induced pain. animal study; preclinical research / 1 linked research note PubMed 39322049
  36. The Effects of Cannabinoids on Pro- and Anti-Inflammatory Cytokines: A Systematic Review of In Vivo Studies. systematic review or meta-analysis; evidence still limited / 1 linked research note PubMed 33998900
  37. Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. animal study; mechanism-focused research / 1 linked research note PubMed 23415610
  38. Cannabigerol Mitigates Haloperidol-Induced Vacuous Chewing Movements in Mice. animal study; preclinical research / 1 linked research note PubMed 39699828
  39. Low-Dose Administration of Cannabigerol Attenuates Inflammation and Fibrosis Associated with Methionine/Choline Deficient Diet-Induced NASH Model via Modulation of Cannabinoid Receptor. animal study; mechanism-focused research / 1 linked research note PubMed 36615835
  40. Cannabigerol attenuates liver fibrosis via AMPK activation: Regulation of lipid metabolism, inflammation, and hepatic stellate cell activation. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 40818359
  41. Medical Cannabis Activity Against Inflammation: Active Compounds and Modes of Action. narrative or expert review; evidence still limited / 1 linked research note PubMed 35614947
  42. Targeting Vascular and Inflammatory Crosstalk: Cannabigerol as a Dual-Pathway Modulator in Rosacea. animal study; mechanism-focused research / 1 linked research note PubMed 40725084
  43. Cannabigerol Reduces Lipid Peroxidation Influencing Oxidative Stress and Inflammation Signaling Pathways in Melanocytes Exposed to UVA Radiation. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 41914282
  44. Cannabigerol Exerts In Vivo and In Vitro Anti-Inflammatory Effects via Inhibition of the MAPK and NF-κB Pathways. animal study; mechanism-focused research / 1 linked research note PubMed 41423277
  45. Cannabigerol Alleviates Liver Damage in Metabolic Dysfunction-Associated Steatohepatitis Female Mice via Inhibition of Transforming Growth Factor Beta 1. animal study; mechanism-focused research / 1 linked research note PubMed 40362835
  46. High Cannabigerol Hemp Extract Moderates Colitis and Modulates the Microbiome in an Inflammatory Bowel Disease Model. animal study; preclinical research / 1 linked research note PubMed 39009468
  47. Sphingolipid metabolism and insulin resistance - Does cannabigerol protect against experimental colitis induced by high-fat high-sucrose diet? animal study; mechanism-focused research / 1 linked research note PubMed 41056638
  48. Cannabigerol and cannabichromene in Cannabis sativa L. narrative or expert review; evidence still limited / 1 linked research note PubMed 36654096
  49. The Use of Cannabinoids in Colitis: A Systematic Review and Meta-Analysis. systematic review or meta-analysis; evidence still limited / 1 linked research note PubMed 29562280
  50. Orally Administered CBD/CBG Hemp Extract Reduces Severity of Ulcerative Colitis and Pain in a Murine Model. animal study; preclinical research / 1 linked research note PubMed 40943856
  51. Cannabigerol as an anti-inflammatory agent altering the level of arachidonic acid derivatives in the colon tissue of rats subjected to a high-fat high-sucrose diet. animal study; preclinical research / 1 linked research note PubMed 39128189
  52. Development of a Rapid LC-MS/MS Method for the Quantification of Cannabidiol, Cannabidivarin, Δ9-Tetrahydrocannabivarin, and Cannabigerol in Mouse Peripheral Tissues. animal study; evidence still limited / 1 linked research note PubMed 28343385
  53. Efficacy of combined therapy with fish oil and phytocannabinoids in murine intestinal inflammation. animal study; preclinical research / 1 linked research note PubMed 32996187
  54. Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages. animal study; mechanism-focused research / 1 linked research note PubMed 27498155
  55. Cannabis compounds exhibit anti-inflammatory activity in vitro in COVID-19-related inflammation in lung epithelial cells and pro-inflammatory activity in macrophages. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 33446817
  56. Phytocannabinoids Act Synergistically with Non-Steroidal Anti-Inflammatory Drugs Reducing Inflammation in 2D and 3D In Vitro Models. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 36559009
  57. Therapeutic Potential of Phytocannabinoid Cannabigerol for Multiple Sclerosis: Modulation of Microglial Activation In Vitro and In Vivo. animal study; mechanism-focused research / 1 linked research note PubMed 36830745
  58. Cannabigerol Attenuates Memory Impairments, Neurodegeneration, and Neuroinflammation Caused by Transient Global Cerebral Ischemia in Mice. animal study; preclinical research / 1 linked research note PubMed 40869376